Ventyx Biosciences (NASDAQ:VTYX) Rating Lowered to “Hold” at Wells Fargo & Company

Ventyx Biosciences (NASDAQ:VTYX) was downgraded by Wells Fargo & Company from a “strong-buy” rating to a “hold” rating in a report issued on Wednesday,Zacks.com reports.

Several other equities analysts have also commented on the stock. Lifesci Capital reaffirmed a “market perform” rating and set a $14.00 price target on shares of Ventyx Biosciences in a research report on Thursday. Canaccord Genuity Group downgraded Ventyx Biosciences from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $16.00 to $14.00 in a report on Thursday. HC Wainwright cut Ventyx Biosciences from a “buy” rating to a “neutral” rating and set a $14.00 target price on the stock. in a report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Ventyx Biosciences in a research report on Wednesday, October 8th. Finally, Oppenheimer downgraded Ventyx Biosciences from an “outperform” rating to a “market perform” rating in a report on Thursday. Eight research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Reduce” and an average price target of $14.86.

Ventyx Biosciences Trading Down 0.2%

Shares of NASDAQ:VTYX opened at $13.81 on Wednesday. The stock’s 50-day moving average price is $9.27 and its two-hundred day moving average price is $5.28. Ventyx Biosciences has a 12-month low of $0.78 and a 12-month high of $25.00. The firm has a market cap of $985.48 million, a price-to-earnings ratio of -9.21 and a beta of 1.23.

Ventyx Biosciences (NASDAQ:VTYX) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.13. As a group, research analysts forecast that Ventyx Biosciences will post -2.09 earnings per share for the current fiscal year.

Insider Transactions at Ventyx Biosciences

In other news, CEO Raju Mohan sold 47,345 shares of the company’s stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $7.72, for a total value of $365,503.40. Following the completion of the sale, the chief executive officer owned 2,372,863 shares of the company’s stock, valued at $18,318,502.36. This represents a 1.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider John Nuss sold 12,675 shares of the stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $7.72, for a total value of $97,851.00. Following the completion of the sale, the insider owned 489,481 shares of the company’s stock, valued at approximately $3,778,793.32. This trade represents a 2.52% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 14.49% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Ashton Thomas Private Wealth LLC purchased a new stake in Ventyx Biosciences during the 2nd quarter worth $71,000. Affinity Asset Advisors LLC purchased a new position in Ventyx Biosciences in the 2nd quarter valued at about $9,707,000. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Ventyx Biosciences by 8.4% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 945,206 shares of the company’s stock valued at $2,023,000 after acquiring an additional 73,601 shares in the last quarter. Pallas Capital Advisors LLC purchased a new stake in shares of Ventyx Biosciences during the second quarter worth about $38,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Ventyx Biosciences in the second quarter worth about $148,000. 97.88% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Ventyx Biosciences

Here are the key news stories impacting Ventyx Biosciences this week:

• Positive Sentiment: Lilly confirms definitive agreement to acquire Ventyx for $14.00 per share (≈$1.2B total), providing a clear cash exit and a floor under the stock while closing risk and timing remain uncertainties. Lilly to acquire Ventyx Biosciences
• Positive Sentiment: UBS begins coverage with a Buy rating and $20.00 price target, implying material upside from the current market level and signaling confidence in Ventyx’s assets/strategic value to acquirers. UBS coverage reported
• Neutral Sentiment: Wells Fargo reaffirmed an “equal weight” rating with a $14.00 price target — effectively in line with the acquisition price and suggesting limited near-term upside beyond the deal consideration. Wells Fargo note
• Neutral Sentiment: Lifesci Capital and Lifesci-related coverage moved to “market perform”/”hold” around the deal price, indicating analysts are treating the announced transaction as the primary valuation anchor. Lifesci/Lifesci Capital coverage
• Negative Sentiment: Several sell-side firms (Oppenheimer, Canaccord Genuity, Clear Street) issued downgrades or cut enthusiasm for VTYX after the deal — moves that can add selling pressure on any remaining float and reflect concerns about upside beyond the $14 offer. Oppenheimer downgrade Canaccord downgrade
• Negative Sentiment: Multiple law firms have launched investigations and shareholder alerts alleging possible unfair process or inadequate price in the Lilly deal; such litigation can delay closing, raise transaction costs, and add uncertainty around final shareholder recoveries. Kahn Swick & Foti investigation Edelson Lechtzin investigation

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.